The FDA must put biotech at its center or continue to cede early research to China
Last month, the FDA launched TrialBlazer, intended to streamline the IND path and bring early clinical trials and medical innovation home to the U.S. It’s a start, but new agency leadership must see…
Read the full articleYou might also wanna read
Medicinal plants used to treat infectious diseases in French Polynesia: an ethnobotanical survey and antibacterial evaluation
archimer.ifremer.fr·just now
A standardized method to monitor marine litter in submarine canyons: implementation in Atlantic and Mediterranean reef ecosystems
archimer.ifremer.fr·just now
Women in Nonequilibrium Statistical Physics, 7–11 Sep 2026 at KU Leuven (Belgium).
fys.kuleuven.be·just now
Oceanographic parameters associated with spatial occurrence of cephalopods in standardized demersal fishing trawls in the NE Atlantic
archimer.ifremer.fr·just now
BPI Asia Digital Series
bioprocessintl.com·just now
Global wind giant snaps up state’s “biggest” wind project as turbine suppliers turn developers
Renew Economy·44m ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.